Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Detalles Bibliográficos
Autores principales: Vehreschild, Maria J. G. T., Taori, Surabhi, Goldenberg, Simon D., Thalhammer, Florian, Bouza, Emilio, van Oene, Joop, Wetherill, Graham, Georgopali, Areti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315086/
https://www.ncbi.nlm.nih.gov/pubmed/30406879
http://dx.doi.org/10.1007/s10096-018-3410-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315086/
https://www.ncbi.nlm.nih.gov/pubmed/30406879
http://dx.doi.org/10.1007/s10096-018-3410-8

Ejemplares similares